3SBIO (01530.HK) stock is soaring 5.19% in pre-market trading on Wednesday, following the company's announcement of robust financial results for the fiscal year and a final dividend declaration.
The Chinese biopharmaceutical company reported impressive financial metrics, including revenue of RMB 9,108 million and a gross profit of RMB 7,828.4 million. The company maintained a high gross margin of 86%, demonstrating strong operational efficiency. 3SBIO's EBITDA reached RMB 3,173.8 million, with adjusted EBITDA slightly higher at RMB 3,402.3 million. The company also posted a basic earnings per share (EPS) of RMB 0.86.
Investors are particularly encouraged by 3SBIO's announcement of a final dividend of HKD25 cents per share, signaling confidence in the company's financial health and commitment to shareholder returns. This combination of strong financial performance and generous dividend payout appears to be driving the significant pre-market surge in 3SBIO's stock price.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。